Browse News
Filter News
Found 212 articles
-
Top 5 Companies Hiring in San Diego
4/11/2024
Looking for a biopharma job in San Diego? Check out these top five companies hiring life sciences professionals like you. -
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
3/16/2024
GSK plc announced statistically significant and clinically meaningful overall survival results from Part 1 and progression-free survival results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial in adult patients with primary advanced or recurrent endometrial cancer.
-
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
3/11/2024
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the fourth quarter and year ended December 31, 2023 and provided a business update.
-
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
2/29/2024
AnaptysBio, Inc. today announced that Daniel Faga, president and chief executive officer, will participate in a panel discussion at TD Cowen’s 44th Annual Health Care Conference.
-
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
1/31/2024
AnaptysBio, Inc. today announced that Daniel Faga, president and chief executive officer, will present at Guggenheim’s 6th Annual Biotechnology Conference.
-
Tr1X, Inc. Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T (Treg) and CAR-Treg Cell Therapies to Treat and Potentially Cure Autoimmune and Inflammatory Diseases
1/17/2024
Tr1X, Inc. announced its emergence from stealth with a $75 million Series A financing to bring universal allogeneic regulatory T and CAR-Treg cell therapies to the clinic to treat and potentially cure autoimmune and inflammatory diseases.
-
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
11/27/2023
AnaptysBio, Inc. (Nasdaq: ANAB) today announced an exclusive license agreement for Centessa Pharmaceuticals’ (NASDAQ: CNTA) blood dendritic cell antigen 2 (BDCA2) modulator antibody portfolio, including lead asset CBS004 and related family of backup antibodies, for the treatment of autoimmune and inflammatory diseases.
-
BioSpace has published its annual 2024 Best Places to Work list.
-
BioSpace Announces 2024 Best Places to Work in Biopharma Winners
11/7/2023
BioSpace, the leader in biopharma news and careers has published its 2024 Best Places to Work list.
-
Anaptys Named a BioSpace 2024 Best Places to Work Winner
11/7/2023
AnaptysBio, Inc., a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced that, for the second year in a row, it has been named a BioSpace 2024 Best Place to Work in the small employer category.
-
Novel Immune Modulator Has Potential to Change Treatment Approach in Rheumatoid Arthritis and Ulc...
11/3/2023
A first-in-class clinical trial will initiate this quarter to determine if a checkpoint agonist can down-regulate activated T cells to help reduce inflammation and tissue damage in patients with moderate-to-severe ulcerative colitis (UC). -
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
11/2/2023
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the third quarter ended September 30, 2023 and provided a business update.
-
Anaptys Announces Participation in November 2023 Investor Conferences
11/1/2023
AnaptysBio, Inc. announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team are scheduled to participate in multiple upcoming investor conferences in November:
-
The company’s experimental lgG4 antibody met the primary endpoint in a late-stage study of the rare skin disease. AnaptysBio will submit an application to the FDA by the third quarter of 2024.
-
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
10/11/2023
AnaptysBio, Inc. today announced two upcoming presentations at the 32nd European Academy of Dermatology and Venerology (EADV) Congress in Berlin, Germany, Oct. 11-14, 2023.
-
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
10/9/2023
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive top-line results from its global Phase 3 GEMINI-1 trial evaluating the safety and efficacy of imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP) flares.
-
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
10/9/2023
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual R&D event for the investment community on rosnilimab, a PD-1 agonist antibody, at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25.
-
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
9/18/2023
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has appointed John Orwin chairman of the AnaptysBio Board of Directors.
-
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
9/12/2023
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, and Dr. Paul Lizzul, chief medical officer, will present at the Stifel 2023 Immunology and Inflammation Virtual Summit later this month.
-
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
8/7/2023
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the second quarter ended June 30, 2023 and provided a business update.